Articles tagged with Metastasis
A study at Dana-Farber Cancer Institute found that a narrow subset of myeloma cells is responsible for metastasis. The researchers identified 11 genes with functional roles in metastasis and proposed these as potential targets for therapies.
Hepatitis B virus (HBV) infection is associated with a complex tumor microenvironment in hepatocellular carcinoma (HCC), leading to carcinogenic progression. Targeted therapies targeting the microenvironment offer promise for treating this disease.
Researchers have found that blocking the CCR5 receptor with an HIV drug can significantly reduce metastasis to the bone in prostate cancer. This breakthrough suggests a potential new treatment approach for patients with advanced prostate cancer.
Researchers have found that specific cells are required for the spread of breast cancer, which could lead to new anti-cancer therapies and improve predictive tests. The study combined tumor cells from patients with breast cancer with laboratory models and found a correlation between high MenaINV levels and metastasis.
Researchers found high-dose interleukin-2 to be effective in metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, achieving durable complete responses in a selected population. The therapy's efficacy and safety were confirmed, offering an alternative treatment option for carefully selected patients.
Research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. High expression of PDL1 is common in both glioblastoma and brain metastases, making immune checkpoint inhibitors a promising treatment option.
Researchers at MD Anderson Cancer Center have identified a protein complex called CSN and its subunit CSN6 as a key factor in cancer development. The study found that inhibiting CSN6 can quickly destabilize the master cancer gene Myc, greatly impairing tumor growth and metastasis.
Researchers found that cirmtuzumab induces senescence in cancer stem cells, degrading their ability to grow and metastasize. Ovarian cancer patients with high levels of ROR1 experienced more aggressive forms of the disease, highlighting the potential of this antibody therapy as a targeted treatment.
Researchers at NUS and their collaborators developed a novel scoring scheme that predicts the ability of cancer cells to spread. The system monitors epithelial-mesenchymal transition (EMT) mechanism, a key process in metastasis, and has shown good correlation with previously published EMT signatures.
Researchers identified a cellular culprit in metastasis, finding that an overabundance of Frizzled-2 and its activator Wnt5 triggers EMT in cancer cells. This discovery informs the design of new treatments to prevent or delay metastasis.
A phase 2 clinical trial found that adding sargramostim to ipilimumab improved overall survival in patients with metastatic melanoma. The combination treatment also had lower toxicity compared to ipilimumab alone.
Cancer cells use genetic circuits as a three-way switch to form both cancer stem cells and circulating tumor cells, leading to metastasis. Researchers found significant correspondence between the operation of these two switches, suggesting a mechanism that would confer 'stemness' on hybrid cancer cells.
A new lab device developed by Johns Hopkins engineers provides a clear view of how tumor cells spread through the body, causing over 90% of cancer-related deaths. By studying the movement of individual cancer cells, researchers aim to uncover new ways to keep cancer in check and develop effective treatment strategies.
Ludwig researchers find ASPP2 acts as a molecular switch to regulate EMT and MET, crucial processes in cancer progression. Poor ASPP2 expression correlates with lower patient survival rates in liver and breast tumors.
Research at Beth Israel Deaconess Medical Center identified an unexpected link between the transcription factor FOXP2 and metastatic colonization of breast cancer. Silencing FOXP2 enables breast cancer cells to acquire malignant traits, facilitating their survival and proliferation.
Researchers discovered that high levels of the inhibitor TIMP-1 induce local inflammation in liver tissue, allowing tumor cells to form metastases. By understanding this mechanism, scientists can develop new treatments to prevent cancer progression and metastasis formation.
Researchers created a novel method for cell migration by mimicking the connective tissue environment, allowing cells to move in a controlled direction. This breakthrough could lead to new approaches in combating cancer metastasis and inflammation.
Weian Zhao, a UCI stem cell scientist, has been awarded the prestigious NIH New Innovator Award to create stem cell-based detection methods for cancer. His project aims to engineer smart stem cell systems to target cancer cells and improve treatment outcomes.
A study published in the Journal of the National Cancer Institute finds that osteoporosis treatment may also benefit breast cancer patients by slowing skeletal metastasis. Women who took oral bisphosphonates had a reduced risk of bone metastases, with longer medication use resulting in greater reduction.
The CLEOPATRA study demonstrated a significant survival benefit of 15.7 months with the combination therapy, outperforming previous studies. The long-term safety profile and cardiac safety were also maintained.
Researchers at Dana-Farber Cancer Institute have developed a novel compound that impedes the spread of multiple myeloma to bones in mice. By targeting the microenvironment, the compound alters the bone marrow environment, making it less hospitable to cancer cells, and slows disease progression and prolongs survival.
A study found that postpartum mice develop metastatic disease due to dying tumor cells triggering anti-inflammatory cytokines that promote wound healing. Mice lacking a receptor for macrophage clearance of dying cells did not develop metastasis, highlighting potential targets for limiting postpartum breast cancer severity.
A Massachusetts General Hospital study analyzed circulating tumor cells and found increased expression of extracellular matrix genes, which could be a novel therapeutic target for pancreatic cancer. The study also identified distinct classes of pancreatic CTCs with unique gene expression patterns.
A new study by MD Anderson Cancer Center researchers found that cancer cells traveling to other sites have different energy needs from their original tumor site counterparts. The study suggests that targeting the protein PGC-1 may be a potential therapeutic approach for breast cancer patients.
A team of Stanford researchers has developed a protein therapy that disrupts the process of metastasis, which causes cancer cells to break away and spread. The treatment uses a harmless version of Axl protein that acts like a decoy to prevent Gas6 proteins from linking with it.
The European Society for Medical Oncology calls for high-quality research and clinical trials for advanced breast cancer. Key areas of focus include treatment strategies for patients with liver or lung metastases, HER2-positive disease, and men receiving aromatase inhibitors.
Scientists at VCU Massey Cancer Center have developed a new molecular imaging approach that can image bone metastases from prostate cancer with greater accuracy than existing methods. The new method detects the gene AEG-1, which is expressed in most cancers but not in healthy cells.
A study found that single fraction radiation therapy (SFRT) is equally effective as multiple fraction radiation therapy (MFRT) in improving patients' pain, function, and quality of life, including for those with excluded characteristics. The results support the generalizability of prior randomized controlled trials to real-world practice.
A meta-analysis of 757 Stage IV NSCLC patients found that factors such as timing of metastases and lymph node involvement impact overall survival. The study identified three risk groups with different five-year OS rates, and highlighted the importance of identifying patients who are most likely to benefit from aggressive treatments.
A UK study has identified a novel molecule called Arylquin 1 that induces Par-4 secretion from normal cells, killing cancer cells while leaving normal cells unharmed. The researchers found that Arylquin 1 binds to vimentin, displacing the Par-4 for secretion and may be useful in inhibiting tumor metastasis.
Recent EORTC Imaging Group review highlights MRI and PET's potential for early detection of bone metastases and monitoring treatment response. The study emphasizes the need to overcome current limitations, such as those related to imaging techniques' sensitivity and specificity.
Researchers found that the protein RBM4, crucial to gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. This discovery offers a new route toward therapies targeting altered genetic pathways that allow cancer cells to proliferate and spread.
A new study by UNC researchers led by Kathleen Caron, Ph.D., shows that deleting CXCR7 allows adrenomedullin to run rampant, triggering enlarged heart and overgrowth of lymphatic vessels. The study highlights the importance of understanding the role of CXCR7 in cardiovascular health.
Scientists at UC San Diego have identified the UBC13 enzyme as a key regulator of breast cancer metastasis, allowing them to potentially block the spread of the disease. The study found that inhibiting this enzyme may prevent metastasis in breast cancer cells.
Researchers at Johns Hopkins Medicine discover that tumor cells can spread through lymphatic vessels by releasing signaling molecules, which attract and facilitate the growth of new blood vessels. The HIV drug maraviroc blocks these signals, preventing breast cancer metastasis when combined with a VEGF-blocking drug.
Researchers identify protein p66ShcA as a biomarker for predicting breast cancer outcomes and identifying poor-prognosis cancers. The discovery aids understanding of epithelial to mesenchymal transition, a process enabling tumor cells to metastasize.
Scientists have identified a novel gene that predicts both breast cancer relapse and response to chemotherapy, enabling doctors to classify patients for more effective treatment. The discovery could help reduce metastasis and increase the effectiveness of chemotherapy.
Cancer cells that break away from tumors can prefer soft environments for growth and proliferation, researchers at the University of Illinois found. The study suggests that this preference may explain why soft tissues are more vulnerable to cancer metastasis and recurrence.
Researchers at Cold Spring Harbor Laboratory have discovered a new function of the body's most important tumor-suppressing protein, p53. A previously unknown variant of p53 called p53-psi reduces cell adhesion and promotes metastatic potential by interacting with cyclophillin D and generating reactive oxygen species.
A Cincinnati Cancer Center study finds that SapC-DOPS, a combination of lysosomal protein saposin C and phospholipid DOPS, targets and kills cancer cells, including those from breast and lung cancers. The treatment showed promise in animal models, with some tumors completely cured within 24 hours.
Researchers at Université catholique de Louvain successfully identified a family of pharmaceutical compounds that prevent the formation of human tumor metastasis. The study found that mitochondria can promote cell migration leading to metastasis, which can be blocked by specific antioxidants.
Scientists discovered a regulatory network contributing to abnormal cell proliferation in diseases like cancers and psoriasis. MicroRNA miR-21 is degraded through PAPD5, which breaks the pathway's disruption in many cancers.
A new study suggests that cancer metastasis, the spread of tumors from one part of the body to another, may occur through pure chance. Researchers used statistical models to show that 'common' cancer cells circulating in the bloodstream could, on rare occasions, cause metastasis.
Scientists at Salk Institute identify gene DIXDC1 that stops cancer cells from spreading, opening new avenues for treating aggressive lung and other cancers. The discovery provides hope for patients with limited treatment options.
Researchers successfully silenced chemokine receptor 4 in SH-SY5Y cells, inhibiting neuroblastoma cell invasion. This approach may provide a new therapeutic strategy for blocking neuroblastoma metastasis.
Researchers at MD Anderson Cancer Center have discovered that circulating tumor cells (CTCs) rely on the HER3 receptor protein to metastasize to the omentum, a fatty tissue covering abdominal organs. High expression of HER3 is associated with shorter survival in ovarian cancer patients.
Researchers isolated breast cancer cells from patients' blood and expanded them in the lab, identifying new mutations and drug susceptibility. The study found a promising drug, Ganetspib, effective in killing tumor cells with specific genetic mutations.
Researchers at Rockefeller University have identified a protein called TARBP2 that triggers breast cancer's spread by blocking other proteins linked to neurodegeneration. This finding suggests new cancer therapies targeting this 'master regulator' could be effective.
A new study published in the Journal of the American College of Surgeons reports that surgical resection improves survival among metastatic melanoma patients with limited liver disease. The five-year survival rate for surgical patients was 30%, compared to 6.6% for nonsurgical patients.
The phase III RECOURSE trial found that TAS-102 improves overall and progression-free survival in patients with metastatic colorectal cancer refractory to standard therapies. The study showed a median overall survival of 7.1 months for TAS-102, compared to 5.3 months for placebo.
A study by Princeton University researchers found that the Metadherin gene, implicated in promoting breast cancer tumors, only stimulates growth when bound to its partner protein SND1. The research reveals that MTDH plays a role in both initial tumor growth and metastasis, but not normal cell growth or development.
Adding MM-398 to standard treatment for metastatic pancreatic cancer improves overall and progression-free survival, according to a phase III trial. The combination therapy showed significant benefits over standard treatment alone, but with higher gastrointestinal side effects.
Experts cite five historical misconceptions in brain metastases research, including assuming all histologies are equal and neglecting total tumor burden. A new article calls for 'fresh thinking' and critical analyses to advance treatment.
Brain cancer specialists argue that current science is guiding compromising care, emphasizing the need for individualized treatment approaches. They identify five misconceptions that lead to poorer care, including assuming all tumor cell types act similarly and neglecting important biological differences.
Researchers at Albert Einstein College of Medicine will study how breast cancer cells move and spread in the body. They aim to develop a test that predicts which breast cancer tumors will metastasize, based on the presence of a trio of cells called a tumor microenvironment of metastasis.
Researchers found that restricting food to nematode worms triggers a state of arrested development, allowing them to live twice as long as normal. The study hints at an easier way to achieve human longevity and has implications for cancer research.
A new protein variant called VEGF-Ax discovered by Cleveland Clinic researchers slows the development of new blood vessels necessary for tumors to expand and metastasize. This discovery could lead to new diagnostic tools and improved treatments to reduce cancer spread, according to Dr. Paul Fox.
A new molecular breast imaging protocol using a higher dose of Tc-99m filtered sulfur colloid has been shown to improve the detection of advanced breast cancer. Imaging performed the day prior to surgery was more sensitive than imaging on the day of surgery, detecting 76% versus 49% of cases with metastasized lymph nodes.
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A Cornell research team has developed a new microfluidic device to isolate and study the most aggressive cancer cells. The device separates these cells from less aggressive ones, enabling researchers to analyze molecular changes that contribute to metastasis.